Results 101 to 110 of about 166 (149)

Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference Product

Ophthalmology and Therapy
Introduction ABP 938 is being developed as a biosimilar candidate to aflibercept reference product (RP), a biologic used for certain angiogenic eye disorders.
Neungseon Seo, Xiaoyan Guan, Tian Wang, Hyo S. Helen Chung, Mats Wikström, Rupa Padaki, Kevin Kalenian, Scott Kuhns, Kelli Matthies, Jill Crouse-Zeineddini, Helen Y. Wong, Michael Ng, Ian N. Foltz, Shawn Cao, Jennifer Liu   +14 more
doaj   +1 more source

Comparative physicochemical and structural characterisation studies establish high biosimilarity between BGL-ASP and reference insulin aspart

Scientific Reports
Biosimilar insulin analogues are increasing market access for diabetic patients globally. Scientific establishment of biosimilarity is cornerstone of this key change in the medical landscape.
Nikhil S. Ghade, Damodar K. Thappa, Jeseena Lona, Archana R. Krishnan, Sanjay M. Sonar   +4 more
doaj   +1 more source

Changes In The Prices Of Reference Biotechnology Products By The Penetration Of Biosimilars Into The Turkish Pharmaceutical Market [PDF]

Value in Health, 2015
Tuna, E, Kockaya, G
openaire   +1 more source

Assessing Functional Similarity of Biosimilar ABP 654 and Ustekinumab in Samples from Patients with Crohn’s Disease

Journal of Inflammation Research
Ian N Foltz,1 Kevin Gaida,2 Helen Y Wong,1 Michael Ng,1 Marijana Busch,1 Jennifer L Liu3 1Amgen Research, Department of Therapeutic Discovery, Amgen Inc., Burnaby, BC, V5A1V7, Canada; 2Research and Development, Amgen Inc., Thousand Oaks, CA, 91320, USA ...
Foltz IN, Gaida K, Wong HY, Ng M, Busch M, Liu JL   +5 more
doaj  

The Impact of Biosimilar Launch on Molecule Price and Pharmaceutical Expense: The Case of the Insulin Glargine in Italy [PDF]

Value in Health, 2017
A Tettamanti, L Cioni, C Tucci
openaire   +1 more source

Key Regulatory Considerations for the Development of Biosimilar Pharmaceutical Products

IOSR Journal of Pharmacy (IOSRPHR), 2014
openaire   +1 more source

Risk management in the distribution process of biosimilar products in the pharmaceutical industry

, 2016
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Can biosimilar products be interchangeable? Pharmaceutical perspective in the implementation of biosimilars in oncology

Journal of Oncology Pharmacy Practice, 2021
Objective To evaluate the safety in the interchangeability of biosimilar products approved for cancer treatment from a pharmaceutical perspective. Methods A literature review was carried out using the descriptors “Biosimilar ...
José Cleberson Santos Soares, Iago Dillion Lima Cavalcanti, Juliana Lúcia de Albuquerque Vasconcelos   +2 more
openaire   +2 more sources

Gel Electrophoretic Methods for The Analysis of Biosimilar Pharmaceuticals Using The Example of Recombinant Erythropoietin

Bioanalysis, 2013
Due to their versatility and cost-effectiveness, gel electrophoretic methods provide an important set of tools for the analysis of therapeutic proteins. As an increasing number of biosimilar pharmaceuticals are entering the market, techniques are required that allow reliable demonstration of comparability of these products with the reference products ...
Mario Thevis, Christian Reichel
exaly   +3 more sources

Addressing the health technology assessment of biosimilar pharmaceuticals

Current Medical Research and Opinion, 2010
Abstract The growing number of biosimilars presents challenges to regulatory and health technology assessment (HTA) systems. This paper illustrates these challenges by focusing on biosimilars used in the oncological setting. In particular, discordances between data required by regulatory and HTA authorities potentially deprive patients of effective ...
Alan, Stewart, Philip, Aubrey, Jonathan, Belsey   +2 more
openaire   +2 more sources